The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.
The AEX-Index in Amsterdam advanced 6.06, or 1.8 percent, to 349.26. Belgium’s Bel20 Index rose 34.75, or 1.4 percent, to 2,557.71. Luxembourg’s LuxX Index gained 1 percent to 1,413.83.
Amsterdam Commodities NV (ACOMO NA): The world’s largest trader of spices said full-year net income rose 47 percent to 15.5 million euros ($21.7 million). Amsterdam Commodities fell 1.9 percent to 10.35 euros.
ICT Automatisering NV (ICT NA): The Dutch software maker reported full-year profit of 6.4 million euros on revenue of 84.5 million euros. ICT increased 1.9 percent to 5.25 euros.
Unilever NV (UNA NA): The world’s second-largest consumer-goods maker was raised to “buy” from “hold” at ING Group NV. Along with Danone, it remains a top pick at Morgan Stanley. Unilever gained 0.7 percent to 21.15 euros.
Van Lanschot NV (LANS NA): The oldest independent Dutch bank reported full-year profit of 65.7 million euros compared with a loss of 14.8 million euros a year earlier. The company resumed its dividend payment. Van Lanschot climbed 3.4 percent to 31.55 euros.
International Brachytherapy SA (IBT BB): Eckert & Ziegler AG (EUZ GY), the majority owner of the Belgian maker of tumor-fighting implants, said it has made an approach to buy Theragenics Corp. (TGX US), either directly or through its Belgian unit, for about $74 million in cash. Theragenics’s board rejected the $2.20-a-share offer, Eckert & Ziegler said. International Brachytherapy climbed 2.2 percent to 2.85 euros.
TiGenix NV (TIG BB): The developer of treatments for damaged joints that plans to merge with Cellerix SA posted a full-year net loss of 15.7 million euros and said it had 5.6 million euros of cash and short-term investments left on Dec. 31. TiGenix was unchanged at 1.31 euros.
UCB SA (UCB BB): The maker of the Cimzia arthritis medicine failed to win the backing of advisers to the European Medicines Agency to market Xyrem as a treatment for fibromyalgia, associated with chronic muscle pain and fatigue, in Europe. UCB rose 1.2 percent to 25.96 euros.